| Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up HS Rugo, RS Finn, V Diéras, J Ettl, O Lipatov, AA Joy, N Harbeck, ... Breast cancer research and treatment 174, 719-729, 2019 | 400 | 2019 |
| Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial CH Barcenas, SA Hurvitz, JA Di Palma, R Bose, AJ Chien, N Iannotti, ... Annals of Oncology 31 (9), 1223-1230, 2020 | 104 | 2020 |
| Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer C Lobo, G Lopes, O Baez, A Castrellon, A Ferrell, C Higgins, E Hurley, ... Breast cancer research and treatment 123, 427-435, 2010 | 90 | 2010 |
| Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation JA Chirinos, A Castrellon, JP Zambrano, JJ Jimenez, W Jy, LL Horstman, ... Heart Rhythm 2 (5), 525-529, 2005 | 74 | 2005 |
| The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer AB Castrellon, I Pidhorecky, V Valero, LE Raez Oncology Reviews 11 (1), 2017 | 46 | 2017 |
| Chemoprevention of breast cancer AB Castrellon, S Glück Expert review of anticancer therapy 8 (3), 443-452, 2008 | 40 | 2008 |
| Novel strategies to improve the endocrine therapy of breast cancer AB Castrellon Oncology reviews 11 (1), 2017 | 35 | 2017 |
| Progression-free survival outcome is independent of objective response in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced … HS Rugo, RS Finn, K Gelmon, AA Joy, N Harbeck, A Castrellon, H Mukai, ... Clinical breast cancer 20 (2), e173-e180, 2020 | 33 | 2020 |
| Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO … S Hurvitz, R Singh, B Adams, JA Taguchi, D Chan, RA Dichmann, ... Therapeutic advances in medical oncology 10, 1758835918807339, 2018 | 31 | 2018 |
| Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: the CONTROL trial S Hurvitz, A Chan, N Iannotti, E Ibrahim, J Chien, N Chan, A Kellum, ... Proceedings of the 2017 San Antonio Breast Cancer Symposium, 5-9, 2017 | 27 | 2017 |
| Nasopharyngeal carcinoma: alternative treatment options after disease progression BA Arango, AB Castrellon, CA Perez, LE Raez, ES Santos Expert Review of Anticancer Therapy 10 (3), 377-386, 2010 | 23 | 2010 |
| Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases S Glück, A Castrellon American journal of therapeutics 16 (6), 585-590, 2009 | 23 | 2009 |
| Stereotactic radiosurgery and ipilimumab versus stereotactic radiosurgery alone in melanoma brain metastases SM Nguyen, A Castrellon, O Vaidis, AE Johnson Cureus 9 (7), 2017 | 20 | 2017 |
| Crohn’s disease complicated by primary gastrointestinal Hodgkin’s lymphoma presenting with small bowel perforation A Castrellon, PA Feldman, M Suarez, S Spector, L Chua, J Byrnes J Gastrointestin Liver Dis 18 (3), 359-361, 2009 | 19 | 2009 |
| Second-Line Therapy for Non–Small-Cell Lung Cancer BA Arango, AB Castrellon, ES Santos, LE Raez Clinical Lung Cancer 10 (2), 91-98, 2009 | 17 | 2009 |
| Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic … KA Gelmon, M Cristofanilli, HS Rugo, AM DeMichele, AA Joy, ... The Breast Journal 26 (3), 368-375, 2020 | 11 | 2020 |
| Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors LE Raez, K Danenberg, D Sumarriva, J Usher, J Sands, A Castrellon, ... Cancer Drug Resistance 4 (4), 1061, 2021 | 10 | 2021 |
| Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary AB Castrellon, S Glück Clin Adv Hematol Oncol 6 (9), 666-72, 2008 | 10 | 2008 |
| Controversies in the management of stage IIIA non-small-cell lung cancer ES Santos, A Castrellon, M Blaya, LE Raez Expert Review of Anticancer Therapy 8 (12), 1913-1929, 2008 | 9 | 2008 |
| Abstract P5-21-03: Palbociclib (PAL)+ letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2 … HS Rugo, RS Finn, V Dieras, J Ettl, O Lipatov, A Joy, N Harbeck, ... Cancer Research 78 (4_Supplement), P5-21-03-P5-21-03, 2018 | 8 | 2018 |
